Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST

European Neuropsychopharmacology

Volumn 24, Issue 9, 2014, Pages 1500-1505

  Rybakowski, Janusz K ^a   Vansteelandt, Kristof ^b   Remlinger Molenda, Agnieszka ^a   Fleischhacker, W Wolfgang ^c   Kahn, René S ^d   Peuskens, Joseph ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotics; EUFEST; Extrapyramidal symptoms; First episode; Schizophrenia; Treatment

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

AKATHISIA; ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG EXPOSURE; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; ADULT; CHEMICALLY INDUCED; CLINICAL TRIAL; DEPRESSION; EUROPE; EXTRAPYRAMIDAL SYNDROME; FEMALE; MALE; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DEPRESSION; EUROPE; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907598424     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.07.001     Document Type: Article

References (24)

1. Barnes T.R., McPhillips M.A. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int. Clin. Psychopharmacol. 1998, 13(Suppl 3):S49-57.
2. Crossley N.A., Constante M., McGuire P., Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br. J. Psychiatry 2008, 196:434-439.
3. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., Boter H., Keet I.P., Prelipceanu D., Rybakowski J.K., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Kahn R.S. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry 2009, 166:675-682.
4. Docx L., Morrens M., Bervoets C., Hulstijn W., Fransen E., De Hert M., Baeken C., Audenaert K., Sabbe B. Parsing the components of the psychomotor syndrome in schizophrenia. Acta Psychiatr. Scand. 2012, 126:256-265.
5. Fleischhacker W.W., Simma A.M. Managing the prodrome of schizophrenia. Current Antipsychotics; Handbook of Experimental Pharmacology 2012, 125-134. Springer-Verlag, Heidelberg.
6. Fleischhacker W.W., Siu C.O., Bodén R, Pappadopulos E., Karayal O.N., Kahn R.S. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int. J Neuropsychopharmacol. 2013, 16:987-995.
7. Galderisi S., Mucci A., Bitter I., Libiger J., Bucci P., Fleischhacker W.W., Kahn R.S. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur. Neuropsychopharmacol. 2013, 23:193-204.
8. Gerlach J., Korsgaard S., Clemmensen P., Lauersen A.M., Magelund G., Noring U., Povlsen U.J., Bech P., Casey D.E. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatr. Scand. 1993, 87:244-252.
9. Gopal S., Liu Y., Alphs L., Savitz A., Nuamah I., Hough D. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatr. Dis. Treat. 2013, 9:1381-1392.
10. Haddad P.M., Das A., Keyhani S., Chaudhry I.B. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J. Psychopharmacol. 2012, 26(5 Suppl.):15-26.
11. Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J. Clin. Psychiatry 2006, 67:897-903.
12. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
13. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 2009, 70:627-643.
14. Majadas S, Olivares J, Galan J, Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr. Psychiatry 2012, 53:145-151.
15. Miller D.D., Caroff S.N., Davis S.M., Rosenheck R.A., McEvoy J.P., Saltz B.L., Riggio S., Chakos M.H., Swartz M.S., Keefe R.S.E., Stroup T.S., Lieberman J.A. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br. J. Psychiatry 2008, 193:279-288.
16. Molenberghs G., Verbeke G. Models for Discrete Longitudinal Data 2005, Springer-Verlag, New York.
17. Pappa S., Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol. Med. 2009, 39:1065-1076.
18. Penders T.M., Agarwal S., Rohaidy R. Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression. Neuropsychiatr. Dis. Treat. 2013, 9:463-465.
19. Praharaj S.K., Jana A.K., Sarkhel S., Sinha V.K. Acute dystonia, akathisia, and parkinsonism induced by ziprasidone. Am. J. Ther. 2014, 21:e38-e40.
20. Riecher-Rössler A., Rybakowski J.K., Pflueger M.O., Beyrau R., Kahn R.S., Malik P., Fleischhacker W.W. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol. Med. 2013, 43:2571-2582.
21. Rybakowski J.K., Vansteelandt K., Szafranski T., Thys E., Jarema M., Fleischhacker W.W., Kahn R.S., Peuskens J. Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur. Neuropsychopharmacol. 2012, 22:875-892.
22. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W., Davis J.M., Leucht S. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr. Bull. 2012, 38:167-177.
23. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry. 1998, 59(20 Suppl.):22-33.
24. Zhang J.P., Gallego J.A., Robinson D.G., Malhotra A.K., Kane J.M., Correll C.U. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 2013, 16:1205-1218.